Stock Analiz

Evogene Ltd. EVGN

Agricultural Chemicals · data as of November 13, 2026

$0.37Market cap $6M
Open the interactive analysis →

Evogene Ltd. (EVGN) is a industrial company listed in the US with a market value of about $6M. In fiscal year 2025 it had revenue of $4M and net income of -$8M, a net margin of -220.2%.

Its overall Stock Analiz score is 1.6 out of 5 (weak). The strongest part is financial health (4/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of 30% a year, a 5-year average ROIC of -89%.

About Evogene

Evogene is listed in the US and classified in agricultural chemicals. Revenue went from $11M in 2015 to $4M in 2025, a decline of about 10.1% a year. It was profitable in 0 of the last 10 years in our data.

Score: 1.6 / 5

Value0/5
Future growth2/5
Track record2/5
Financial health4/5
Shareholder returns0/5

Checks passed

  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • 5-year revenue growth above 8% a year
  • ROE above 15%
  • More cash than debt, or low debt to equity
  • Interest covered more than 5 times
  • Debt below 3 years of free cash flow
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year free cash flow growth above 10% a year
  • Strong R&D investment or growth above 20%

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S1.5
P/B—
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-232.6%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)-30.9%
Revenue growth (5 yrs, per year)29.9%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-1179.1%
ROIC (5-yr avg.)-89.2%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 10 years

Fiscal year2025202420232022202120202019201820172016
Revenue$4M$6M$3M$2M$930000$1M$753000$2M$3M$7M
Net income-$8M-$16M-$24M-$27M-$28M-$23M-$18M-$21M-$21M-$20M
Free cash flow-$14M-$20M-$22M-$25M-$26M-$20M-$19M-$16M-$17M-$13M
EPS (diluted)$-0.54$-1.04$-1.51$-1.69$-1.76$-1.48$-1.15$-1.31$-1.32$-1.24
Net margin-220.2%-295.6%-800.8%-1590.3%-2988.5%-2247.5%-2405.3%-1188.2%-616.3%-299.6%
ROIC——-145.7%-76.2%-45.6%-42.6%-33.4%-31.6%-25.0%-19.1%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Does Evogene pay a dividend?

Not currently.

Is Evogene a good stock to buy?

We do not give buy or sell advice. Evogene scores 1.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.